LXN plans U.S. launch of Duet fructosamine/glucose monitor in early 1998.
This article was originally published in The Gray Sheet
Executive Summary
LXN CORP. U.S. SHIPMENTS OF DUET O-T-C FRUCTOSAMINE/GLUCOSE MONITOR will begin in early 1998 at the earliest, the firm says. LXN received 510(k) clearance June 13 for over-the-counter sale of the monitor for use by diabetics to measure fructosamine. The firm, which obtained FDA clearance in June 1996 for self-measurement of glucose with the same meter, will defer marketing until it is able to offer both tests together. Discussions with FDA are ongoing to determine if an additional 510(k), or supplemental data to the fructosamine 510(k), would be required to market the Duet for measuring glucose and fructosamine at the same time.
You may also be interested in...
AAM Welcomes Proposal To Update Medicare Part D
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s Wants To Break Into Top Five In India
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
Building Trust In Brands Should Be A Continuous Process For The Self-Care Industry
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: